Premium
Azithromycin and terfenadine: Lack of drug interaction
Author(s) -
Harris Stuart,
Hilligoss Donald M.,
Colangelo Philip M.,
Eller Mark,
Okerholm Richard
Publication year - 1995
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/0009-9236(95)90247-3
Subject(s) - terfenadine , azithromycin , pharmacokinetics , pharmacology , pharmacodynamics , drug interaction , medicine , qt interval , placebo , antibiotics , antibacterial agent , anesthesia , chemistry , biochemistry , alternative medicine , pathology
A double‐blind placebo‐controlled study was conducted in healthy men to determine the effect of co‐administration of azithromycin on the pharmacodynamics and pharmacokinetics of terfenadine. Administration of 500 mg azithromycin for 1 day and 250 mg on 4 subsequent days did not affect the pharmacokinetics of the pharmacologically active terfenadine carboxylate metabolite when 60 mg terfenadine was given twice daily for 12 days, starting 7 days before azithromycin administration. Terfenadine alone resulted in a 0.010 msec increase in the rate‐corrected QT interval (QT c ), but the incremental effects of azithromycin and placebo on QT c in volunteers receiving terfenadine were not statistically different. It is concluded that the potentially life‐threatening disorders that have been attributed to a pharmacokinetic interaction between macrolide antibiotics and terfenadine are unlikely to take place in patients treated simultaneously with azithromycin and terfenadine. Clinical Pharmacology & Therapeutics (1995) 58 , 310–315; doi: